FDA Ortho Panel Will See Second Hip Resurfacing System In Cormet
This article was originally published in The Gray Sheet
Executive Summary
Corin Group's Cormet will be the second hip resurfacing product to go before an FDA advisory committee when the Orthopaedic and Rehabilitation panel considers the device's PMA next month
You may also be interested in...
Hip Resurfacing Technology Aids S&N Stock Gain In Q1 - Index Up 1.1%
Investor enthusiasm for hip resurfacing's market potential was among factors contributing to Smith & Nephew's 21.3% stock price gain in the first quarter
Hip Resurfacing Technology Aids S&N Stock Gain In Q1 - Index Up 1.1%
Investor enthusiasm for hip resurfacing's market potential was among factors contributing to Smith & Nephew's 21.3% stock price gain in the first quarter
Corin’s Cormet 2000 Hip Resurfacing System Is “Approvable With Conditions”
Corin's Cormet 2000 hip resurfacing system requires a postmarket study to address long-term safety concerns, FDA's Orthopedic and Rehabilitation Devices Panel recommended Feb. 22